Search Page

1

Cite

Share

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials.

Mukherjee SD, Coombes ME, Levine M, Cosby J, Kowaleski B, Arnold A. Mukherjee SD, et al. Invest New Drugs. 2011 Oct;29(5):1013-20. doi: 10.1007/s10637-010-9456-9. Epub 2010 May 29. Invest New Drugs. 2011. PMID: 20512397

Cite

Share

2

Cite

Share

Adjuvant therapy for completely resected stage II colon cancer.

Figueredo A, Coombes ME, Mukherjee S. Figueredo A, et al. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005390. doi: 10.1002/14651858.CD005390.pub2. Cochrane Database Syst Rev. 2008. PMID: 18646127 Review.

Cite

Share

3

Cite

Share

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.

Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, Mukherjee SD, Wang L, Blattler C, Wright JJ, Moore MJ. Sridhar SS, et al. Among authors: mukherjee sd. Invest New Drugs. 2011 Oct;29(5):1045-9. doi: 10.1007/s10637-010-9408-4. Epub 2010 Feb 27. Invest New Drugs. 2011. PMID: 20191303 Clinical Trial.

Cite

Share

4

Cite

Share

Early stopping rules in oncology: considerations for clinicians.

Mukherjee SD, Goffin JR, Taylor V, Anderson KK, Pond GR. Mukherjee SD, et al. Eur J Cancer. 2011 Nov;47(16):2381-6. doi: 10.1016/j.ejca.2011.05.019. Epub 2011 Jun 16. Eur J Cancer. 2011. PMID: 21684153 Review.

Cite

Share

5

Cite

Share

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.

Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, Mukherjee SD, Chi KN. Beardsley EK, et al. Among authors: mukherjee sd. Invest New Drugs. 2012 Aug;30(4):1652-9. doi: 10.1007/s10637-011-9722-5. Epub 2011 Jul 23. Invest New Drugs. 2012. PMID: 21785998 Clinical Trial.

Cite

Share

6

Cite

Share

Physician-related facilitators and barriers to patient involvement in treatment decision making in early stage breast cancer: perspectives of physicians and patients.

O'Brien MA, Ellis PM, Whelan TJ, Charles C, Gafni A, Lovrics P, Mukherjee SD, Hodgson N. O'Brien MA, et al. Among authors: mukherjee sd. Health Expect. 2013 Dec;16(4):373-84. doi: 10.1111/j.1369-7625.2011.00712.x. Epub 2011 Sep 16. Health Expect. 2013. PMID: 21923813 Free PMC article.

Cite

Share

7

Cite

Share

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.

Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. Sridhar SS, et al. Among authors: mukherjee sd. Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26. Invest New Drugs. 2013. PMID: 23354849 Clinical Trial.

Cite

Share

8

Cite

Share

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.

Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, Reaume MN, Zhang L, Sridhar SS. Ko YJ, et al. Among authors: mukherjee sd. Lancet Oncol. 2013 Jul;14(8):769-76. doi: 10.1016/S1470-2045(13)70162-1. Epub 2013 May 22. Lancet Oncol. 2013. PMID: 23706985 Clinical Trial.

Cite

Share

9

Cite

Share

A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Azad AA, Beardsley EK, Hotte SJ, Ellard SL, Klotz L, Chin J, Kollmannsberger C, Mukherjee SD, Chi KN. Azad AA, et al. Among authors: mukherjee sd. Invest New Drugs. 2014 Aug;32(4):746-52. doi: 10.1007/s10637-014-0091-8. Epub 2014 Mar 28. Invest New Drugs. 2014. PMID: 24671507 Clinical Trial.

Cite

Share

10

Cite

Share

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ. Spreafico A, et al. Among authors: mukherjee sd. Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5. Epub 2014 May 3. Invest New Drugs. 2014. PMID: 24788563 Free PMC article. Clinical Trial.

Cite

Share